Remodeling genomes with artificial transcription factors (ATFs)

Methods in Molecular Biology

Volumn 649, Issue , 2010, Pages 163-182

  Beltran, Adriana S ^a   Blancafort, Pilar ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 aza 2 dC; artificial transcription factors (ATFs); epigenetics; SAHA; Zinc fingers

Indexed keywords

AZACITIDINE; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; CHROMATIN; DRUG EFFECT; FLOW CYTOMETRY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; EPIGENESIS, GENETIC; FLOW CYTOMETRY; HUMANS; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 80052698739     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-753-2_10     Document Type: Article

References (27)

1. Collingwood, T.N., Urnov, F.D., andWolffe, A.P. (1999) Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription. JMol Endocrinol. 3, 255-275.
2. Ohm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L., Mohammad, H.P., Chen, W., Daniel, V.C., Yu, W., Berman, D.M., Jenuwein, T., Pruitt, K., Sharkis, S.J., Watkins, D.N., Herman, J.G., and Baylin, S.B. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 39, 237-242.
3. Baylin, S.B. (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 1, S4.
4. Ting, A.H., McGarvey, K.M., and Baylin, S.B. (2006) The cancer epigenome-components and functional correlates. Genes Dev. 20, 3215-3231.
5. Jones, P.A. and Baylin, S.B. (2007) The epigenomics of cancer. Cell. 128, 683-692.
6. Jones, P.A. and Laird, P.W. (1999) Cancer epigenetics comes of age. Nat Genet. 2, 163-168.
7. Sims, R.J., III and Reinberg, D. (2008) Is there a code embedded in proteins that is based on post-translational modifications? Nat Rev Mol Cell Biol. 10, 815-820.
8. Palii, S.S. and Robertson, K.D. (2007) Epigenetic control of tumor suppression. Crit Rev Eukaryot Gene Expr. 4, 295-316.
9. Beltran, A., Parikh, S., Liu, Y., Cuevas, B.D., Johnson, G.L., Futscher, B.W., and Blancafort, P. (2007) Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 19, 2791-2798.
10. Beltran, A.S., Sun, X., Lizardi, P.M., and Blancafort, P. (2008) Reprogramming epigenetic silencing: Artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther. 5, 1080-1090.
11. Blancafort, P. and Beltran, A.S. (2008) Rational design, selection and specificity of artificial transcription factors (ATFs): The influence of chromatin in target gene regulation. Comb Chem High Throughput Screen. 11, 146-158.
12. Beltran, A., Liu, Y., Parikh, S., Temple, B., and Blancafort, P. (2006) Interrogating genomes with combinatorial artificial transcription factor libraries: Asking zinc finger questions. Assay Drug Dev Technol. 3, 317-331.
13. Blancafort, P., Magnenat, L., and Barbas, I.I.I.C.F. (2003) Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol. 21, 269-274.
14. Schaefer, J.S. and Zhang, M. (2006) Targeting maspin in endothelial cells to induce cell apoptosis. Expert Opin Ther Targets. 3, 401-408.
15. Zhang, W., Shi, H.Y., and Zhang, M. (2005) Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer. 5, 50.
16. Li, X., Chen, D., Yin, S., Meng, Y., Yang, H., Landis-Piwowar, K.R., Li, Y., Sarkar, F.H., Reddy, G.P., Dou, Q.P., and Sheng, S. (2007) Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol. 2, 298-306.
17. Wozniak, R.J., Klimecki, W.T., Lau, S.S., Feinstein, Y., and Futscher, B.W. 5-Aza-2-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 1, 77-90.
18. Primeau, M., Gagnon, J., and Momparler, R.L. (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2, 177-184.
19. Oshiro, M.M., Watts, G.S., Wozniak, R.J., Junk, D.J., Munoz-Rodriguez, J.L., Domann, F.E., and Futscher, B.W. (2003) Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene. 22, 3624-3634.
20. Livak, K.J. and Schmittgens, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-CT) method. Methods. 4, 402-408.
21. Tallarida, R.J. (2000) Drug synergism and dose-effect data analysis, pp. 15-71. CRC Press, Boca Raton
22. Berenbaum, M.C. (1989) What is synergy? Pharmacol Rev. 2, 93-141.
23. Chou, T.C. and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22, 27-55.
24. Chou, T.C. (1994) Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet. 19, 91-107.
25. Chou, T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 3, 621-681.
26. Reynolds, C.P. and Maurer, B.J. (2005) Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med. 110, 173-183.
27. Meczes, E.L., Pearson, A.D., Austin, C.A., and Tilby, M.J. (2002) Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin. Br J Cancer. 3, 485-489.